Organigram (OGI) Competitors $1.03 -0.03 (-2.83%) Closing price 04:00 PM EasternExtended Trading$1.06 +0.02 (+2.43%) As of 05:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock OGI vs. UPB, CGEM, OPT, AKBA, PGEN, ANAB, MAZE, TRVI, SAGE, and MNMDShould you be buying Organigram stock or one of its competitors? The main competitors of Organigram include Upstream Bio (UPB), Cullinan Therapeutics (CGEM), Opthea (OPT), Akebia Therapeutics (AKBA), Precigen (PGEN), AnaptysBio (ANAB), Maze Therapeutics (MAZE), Trevi Therapeutics (TRVI), Sage Therapeutics (SAGE), and Mind Medicine (MindMed) (MNMD). These companies are all part of the "pharmaceutical products" industry. Organigram vs. Upstream Bio Cullinan Therapeutics Opthea Akebia Therapeutics Precigen AnaptysBio Maze Therapeutics Trevi Therapeutics Sage Therapeutics Mind Medicine (MindMed) Upstream Bio (NASDAQ:UPB) and Organigram (NASDAQ:OGI) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, community ranking, risk, profitability, dividends, media sentiment and valuation. Does the MarketBeat Community prefer UPB or OGI? Organigram received 194 more outperform votes than Upstream Bio when rated by MarketBeat users. However, 100.00% of users gave Upstream Bio an outperform vote while only 70.71% of users gave Organigram an outperform vote. CompanyUnderperformOutperformUpstream BioOutperform Votes4100.00% Underperform VotesNo VotesOrganigramOutperform Votes19870.71% Underperform Votes8229.29% Which has preferable earnings & valuation, UPB or OGI? Upstream Bio has higher earnings, but lower revenue than Organigram. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUpstream Bio$2.37M155.60N/AN/AN/AOrganigram$166.12M0.78-$33.39M-$0.38-2.70 Do insiders and institutionals hold more shares of UPB or OGI? 34.6% of Organigram shares are owned by institutional investors. 0.1% of Organigram shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the media refer more to UPB or OGI? In the previous week, Organigram had 2 more articles in the media than Upstream Bio. MarketBeat recorded 4 mentions for Organigram and 2 mentions for Upstream Bio. Upstream Bio's average media sentiment score of 1.84 beat Organigram's score of 0.47 indicating that Upstream Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Upstream Bio 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Organigram 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is UPB or OGI more profitable? Upstream Bio has a net margin of 0.00% compared to Organigram's net margin of -31.69%. Upstream Bio's return on equity of 0.00% beat Organigram's return on equity.Company Net Margins Return on Equity Return on Assets Upstream BioN/A N/A N/A Organigram -31.69%-8.59%-6.54% Do analysts prefer UPB or OGI? Upstream Bio currently has a consensus price target of $56.50, indicating a potential upside of 721.82%. Given Upstream Bio's higher probable upside, equities research analysts clearly believe Upstream Bio is more favorable than Organigram.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Upstream Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Organigram 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryUpstream Bio beats Organigram on 8 of the 13 factors compared between the two stocks. Remove Ads Get Organigram News Delivered to You Automatically Sign up to receive the latest news and ratings for OGI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OGI vs. The Competition Export to ExcelMetricOrganigramPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$129.37M$6.93B$5.63B$7.83BDividend YieldN/A2.73%4.57%4.00%P/E Ratio-2.707.1623.1218.67Price / Sales0.78221.41388.1791.15Price / CashN/A65.6738.1634.64Price / Book0.566.386.884.23Net Income-$33.39M$142.12M$3.20B$247.15M7 Day Performance-7.66%-4.83%-2.86%-2.16%1 Month Performance-10.87%-7.22%1.72%-5.71%1 Year Performance-52.33%-8.75%9.77%-0.81% Organigram Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OGIOrganigram0.7068 of 5 stars$1.03-2.8%N/A-53.8%$130.00M$166.12M-2.71860UPBUpstream BioN/A$9.87+2.7%$56.50+472.4%N/A$529.44M$2.37M0.0038Positive NewsCGEMCullinan Therapeutics2.1633 of 5 stars$9.03+2.7%$32.86+263.9%-53.2%$528.37MN/A-3.1830OPTOpthea0.7069 of 5 stars$3.41+7.1%$12.00+252.4%-12.8%$524.07M$87,666.000.008Analyst DowngradeShort Interest ↑Analyst RevisionNews CoverageGap UpAKBAAkebia Therapeutics3.5491 of 5 stars$2.40+6.2%$6.75+181.3%-13.8%$523.63M$169.88M-10.43430PGENPrecigen3.5697 of 5 stars$1.78-1.1%$7.00+293.3%+13.1%$521.31M$3.96M-3.24190ANABAnaptysBio2.9926 of 5 stars$16.51-1.3%$35.11+112.7%-12.8%$506.31M$91.28M-2.72100Buyback AnnouncementHigh Trading VolumeMAZEMaze TherapeuticsN/A$11.49+4.5%$25.67+123.4%N/A$503.00M$167.50M0.00121TRVITrevi Therapeutics3.6496 of 5 stars$6.54-3.1%$15.94+143.7%+88.2%$502.70MN/A-14.8620Short Interest ↑SAGESage Therapeutics2.9875 of 5 stars$8.02+3.9%$8.81+9.9%-54.5%$493.08M$41.24M-1.22690Positive NewsMNMDMind Medicine (MindMed)2.3985 of 5 stars$6.47+1.9%$25.11+288.1%-32.3%$487.63MN/A-2.8640Insider TradeAnalyst RevisionNews Coverage Remove Ads Related Companies and Tools Related Companies UPB Competitors CGEM Competitors OPT Competitors AKBA Competitors PGEN Competitors ANAB Competitors MAZE Competitors TRVI Competitors SAGE Competitors MNMD Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OGI) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredTrump’s Treasure Map [Pic inside]We were shown this map by former Presidential Advisor, Jim Rickards, one of the most politically connected men...Paradigm Press | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredAI Boom Takes a Shocking Turn…A potentially historic moment for retirement Let's make the most of this market together. Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Organigram Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Organigram With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy OGI Stock Free OGI Stock Alerts